|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Newport Pharmaceuticals International |
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002297 |
Purpose
The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include:
Signs and symptoms:
Cell-mediated immune system parameters:
Safety parameters:
| Condition | Intervention |
|
Lymphatic Disease HIV Infections |
Drug: Inosine pranobex |
| MedlinePlus related topics: | AIDS Lymphatic Diseases |
| Drug Information available for: | Inosine Inosine pranobex |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind |
| Official Title: | A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Exclusion Criteria
Co-existing Condition:
Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, or gastric ulceration are excluded.
Concurrent Medication:
Excluded:
Critically ill patients or those with CDC-defined AIDS are excluded.
Prior Medication:
Excluded within 1 month of study entry:
Patients with persistent generalized lymphadenopathy (PGL).
Contacts and Locations
More Information
| Study ID Numbers: | 008A, ISO-103-USA |
| First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002297 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|